Sugi Predict

Sugi Predict / Compounds / SCHEMBL17009673

SCHEMBL17009673

SCHEMBL17009673

COC(=O)c1cc([N+](=O)[O-])c(N[C@H]2C[C@@H](C)CC(C)(C)C2)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.36
▸ PDGFRB P09619 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ FLT1 P17948 1/20 0.35
▸ FGFR3 P22607 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ ALDH1A1 P00352 5/20 0.35
▸ MAPT P10636 3/20 0.35
▸ MAPK1 P28482 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HCAR3 P49019 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ HTT P42858 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ SIRT6 Q8N6T7 1/20 0.34
▸ OPRK1 P41145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17009675 1.00 PKM (0.36) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL17009676 1.00 PKM (0.36) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL17009776 0.92 PDGFRB (0.35) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL17009774 0.92 PDGFRB (0.35) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL17009771 0.92 PDGFRB (0.35) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL28644615 0.89 HCAR3 (0.41) PKMALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL28644617 0.89 HCAR3 (0.41) PKMALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL17010404 0.88 PDGFRB (0.46) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL17010459 0.88 PDGFRB (0.46) PKMPDGFRBFGFR1PDGFRAFLT1
SCHEMBL17010458 0.88 PDGFRB (0.46) PKMPDGFRBFGFR1PDGFRAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107949557-B 2-aryl-and 2-aralkyl-benzimidazoles as mIDH1 inhibitors 德国癌症研究公共权益基金会 2021-11-02 — — CN disclosed
CN-108026052-B 5-hydroxyalkyl benzimidazoles as mIDH1 inhibitors 德国癌症研究公共权益基金会 2021-10-08 — — CN disclosed
EP-3319945-B1 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) 2021-04-28 — — EP disclosed
EP-3322694-B1 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS Bayer Pharma AG (DE) 2020-02-19 — — EP disclosed
US-10442772-B2 Benzimidazol-2-amines as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-10-15 — — US disclosed
US-10414734-B2 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-09-17 — — US disclosed
EP-3105209-B1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS Bayer Pharma AG (DE) 2019-08-21 — — EP disclosed
EP-3105210-B1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS Bayer Pharma AG (DE) 2019-01-30 — — EP disclosed
US-10179123-B2 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-15 — — US disclosed
US-20180207137-A1 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-26 — — US disclosed
US-9951027-B2 Benzimidazol-2-amines as MIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-04-24 — — US disclosed
US-20170197922-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) 2017-07-13 — — US disclosed
US-20170197921-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) 2017-07-13 — — US disclosed
WO-2017009325-A1 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-19 — — WO disclosed
WO-2017005674-A1 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-12 — — WO disclosed
EP-3105209-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-12-21 — — EP disclosed
EP-3105210-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-12-21 — — EP disclosed
CN-105980365-A Benzimidazol-2-amines as mIDH1 inhibitors 拜耳医药股份公司 2016-09-28 — — CN disclosed
WO-2015121210-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-08-20 — — WO disclosed
WO-2015121209-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414734-B2 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors HRH1, HRH2, MDN1 PKM 3545/4885PDGFRB 187/4885FGFR1 1083/4885
US-20180207137-A1 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS HRH1, MDN1, NAT1 PKM 3718/4885PDGFRB 217/4885FGFR1 311/4885
US-10179123-B2 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors HRH1, MDN1, NAT1 PKM 3718/4885PDGFRB 217/4885FGFR1 311/4885
US-10442772-B2 Benzimidazol-2-amines as mIDH1 inhibitors HRH1, HRH2, HRH3 PKM 3264/4885PDGFRB 479/4885FGFR1 1068/4885
US-20170197922-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS HRH1, HRH2, HRH3 PKM 3268/4885PDGFRB 477/4885FGFR1 1055/4885
US-20170197921-A1 BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS HRH1, HRH2, HRH3 PKM 3264/4885PDGFRB 479/4885FGFR1 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.